c19early.org COVID-19 treatment researchCOVID-19 treatments

A Multicenter, Open-label, Randomized Study of the Efficacy and Safety of Artlegia (INN: Olokizumab) New Dosing Regimen in Patients With Coronavirus Infection (COVID-19) With Signs of Hyperinflammation

Samsonov et al., NCT05187793, RESET, NCT05187793, Apr 2023
198 patient olokizumab late treatment RCT with results not reported over 3 years after completion.
Important missing comments or errors? Let us know.
Samsonov et al., 1 Apr 2023, Randomized Controlled Trial, Russia, trial NCT05187793 (history) (RESET).
Late treatment
is less effective